Corcept Therapeutics (NASDAQ:CORT), based in Redwood (NYSE:RWT) City, California, is known for its work in pharmaceutical preparations, and Swisher's transactions are part of routine financial activities observed in the company's leadership. The company maintains strong financial health with a "GREAT" rating according to InvestingPro metrics, and investors can mark their calendars for the next earnings report on February 12, 2025. The company maintains strong financial health with a "GREAT" rating according to InvestingPro metrics, and investors can mark their calendars for the next earnings report on February 12, 2025.
Corcept Therapeutics, based in Redwood City, California, is known for its work in pharmaceutical preparations, and Swisher's transactions are part of routine financial activities observed in the company's leadership. The company maintains strong financial health with a "GREAT" rating according to InvestingPro metrics, and investors can mark their calendars for the next earnings report on February 12, 2025.
Corcept Therapeutics, based in Redwood City, California, is known for its work in pharmaceutical preparations, and Swisher's transactions are part of routine financial activities observed in the company's leadership.
In other recent news, Corcept Therapeutics Incorporated has made significant strides in its clinical and financial performance. The company reported a robust increase in third-quarter revenue to $182.5 million, a 48% year-over-year rise, and a net income of $47.2 million. Consequently, Corcept raised its full-year revenue guidance for 2024 to between $675 million and $700 million.
On the clinical front, Corcept's Phase 4 CATALYST study achieved its primary endpoint, showing that Korlym significantly improved blood sugar levels in patients with hypercortisolism and hard-to-control type 2 diabetes. However, the Phase 2 DAZALS study of dazucorilant did not meet its primary endpoint for patients with ALS, but survival data has led to the continuation of an open-label extension study.
Furthermore, Corcept has filed a New Drug Application for relacorilant, a promising treatment for Cushing's syndrome, following positive outcomes from the GRACE trial and supporting results from Phase 3 GRADIENT. These recent developments highlight Corcept Therapeutics' commitment to addressing severe health conditions and its strong financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.